Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 4/20 | 0.42 |
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 12/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614168 | 1.00 | NOS3 (0.42) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL27364270 | 0.84 | LPL (0.37) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL253320 | 0.80 | UHRF1 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29502732 | 0.80 | UHRF1 (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL23496480 | 0.79 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL17053327 | 0.79 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12069605 | 0.79 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL394155 | 0.79 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29502754 | 0.79 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL613614 | 0.79 | LPL (0.47) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713095-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | Chengdu Anticancer Bioscience, Ltd. (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| EP-4263546-B1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2025-07-02 | — | — | EP | disclosed |
| EP-4543888-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4543887-A2 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025003987-A1 | NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2025-01-02 | — | — | WO | disclosed |
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024240088-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE , LTD. (CN) | 2024-11-28 | — | — | WO | disclosed |
| CN-115335057-A | Method for inhibiting casein kinase | 北京原基华毅生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115298183-A | Compounds as casein kinase inhibitors | 北京原基华毅生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-4041731-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-113365985-B | Compound with benzo-seven-membered ring structure, preparation method and application thereof | 博诺康源(北京)药业科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114845711-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-110506044-B | BRD4 inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-05 | — | — | CN | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| CN-107849013-B | Cyanopyrrolidines as DUB inhibitors for the treatment of cancer | 特殊治疗有限公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2022058920-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | NOS3 396/4885NOS2 816/4885NOS1 324/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | NOS3 1685/4885NOS2 2115/4885NOS1 1797/4885 |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | NOS3 577/4885NOS2 727/4885NOS1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.